Etranacogene dezaparvovec (Hemgenix)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: adeno-associated virus vector-based gene therapy (adeno-associated virus serotype 5; AAV5) which delivers a gene encoding the Padua variant of human coagulation factor IX (hFIX-Padua) and results in the recipient producing circulating Factor IX.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

Also known as

  • Generic name: etranacogene dezaparvovec-drlb

References